A controlled study of intermittent and regular administration of rifaximin for the prevention of hepatic encephalopathy and all-cause hospitalisation

Chen Jia; Xiao Xiao; Tong Jin; Wan Xiaoqiang; Zheng Zidan; Peng Peng

doi:10.13406/j.cnki.cyxb.003226

您当前的位置：

首页 >

文章列表页 >

A controlled study of intermittent and regular administration of rifaximin for the prevention of hepatic encephalopathy and all-cause hospitalisation

Clinical research | 更新时间：2025-10-21

- A controlled study of intermittent and regular administration of rifaximin for the prevention of hepatic encephalopathy and all-cause hospitalisation
- Journal of Chongqing Medical University Vol. 48, Issue 5, Pages: 591-596(2023)
- 作者机构：
  
  重庆市第四人民医院/重庆大学附属中心医院消化内科，重庆 400010
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003226
  CLC： R575
- Received：20 October 2022，
  
  Revised：2023-02-24，
  
  Accepted：16 March 2023，
  
  Published：28 May 2023
- 稿件说明：
移动端阅览
陈佳,肖潇,童锦,等.利福昔明间断性及规律性给药预防肝性脑病及全因住院的对照研究[J].重庆医科大学学报,2023,48(5):591-596.

Chen Jia,Xiao Xiao,Tong Jin,et al.A controlled study of intermittent and regular administration of rifaximin for the prevention of hepatic encephalopathy and all-cause hospitalisation[J].Journal of Chongqing Medical University,2023,48(5):591-596.
陈佳,肖潇,童锦,等.利福昔明间断性及规律性给药预防肝性脑病及全因住院的对照研究[J].重庆医科大学学报,2023,48(5):591-596. DOI： 10.13406/j.cnki.cyxb.003226.

Chen Jia,Xiao Xiao,Tong Jin,et al.A controlled study of intermittent and regular administration of rifaximin for the prevention of hepatic encephalopathy and all-cause hospitalisation[J].Journal of Chongqing Medical University,2023,48(5):591-596. DOI： 10.13406/j.cnki.cyxb.003226.

摘要

目的

探究临床中间断性使用利福昔明预防肝性脑病（hepatic encephalopathy， HE）复发的效果是否不劣于规律给药，利福昔明治疗后是否可降低患者因HE及全因住院的次数。

方法

该研究为单中心前瞻性病例对照研究，将纳入的HE患者根据给药方案不同分为2组：间断给药组（利福昔明 400 mg tid，每周连续给药2 d）30例，其中最短给药时间4周，18例疗程3个月；规律给药组（利福昔明 400 mg tid，每天服用）25例，其中24例疗程3个月。比较2组患者在不同给药时间及给药前后因HE及全因住院的差异。

结果

间断给药组与规律给药组相比，服药4周因HE及全因住院的概率差异均无统计学意义（

0.05），服药3个月因HE及全因住院的次数差异均无统计学意义（

0.05）。利福昔明给药后3个月与给药前3个月相比，因HE住院的平均住院次数减少［（0.52±0.86）次vs.（1.12±1

.04）次，

=0.000］、全因住院的平均住院次数减少［（0.90±0.98）次vs.（1.60±1.08）次，

=0.000］。亚组分析发现，间断给药组及规律给药组在给药后3个月与给药前3个月相比较，因HE及全因住院的次数均减少，差异有统计学意义（

0.05）。规律给药组患者大便含真菌的比例更高（4/7 vs. 1/10），但差异无统计学意义（

=0.101）。

结论

间断使用利福昔明预防HE不劣于规律给药。间断或规律使用利福昔明，给药后均可减少患者因HE及全因住院的次数。临床中长期用药需警惕真菌感染风险。

Abstract

Objective

To compare whether intermittent use of rifaximin in clinical practice is no less effective than regular dosing in preventing recurrence of hepatic encephalopathy（HE） and whether rifaximin treatment before and after reduces the number of patients hospitalized for HE and all-cause illness.

Methods

The study was a single-center prospective case-control study in which enrolled HE patients were divided into 2 groups according to different dosing regimens，with a minimum duration of 4 weeks，including intermittent dosing group（rifaximin 400 mg tid， 2 days a week），with 30 patients，18 of whom were treated for 3 months；regular dosing group （rifaximin 400 mg tid， daily），with 25 patients，24 of whom were treated for 3 months. The differences in HE and all-cause hospitalization between the two groups were compared at different dosing times and before and after dosing.

Results

There was no statistically significant difference in the probability of hospitalization for HE and all-cause hospitalization in the intermittent dosing group compared to the regular dosing group at 4 weeks of dosing（

0.05）， and there was either no statistically significant difference in the number of hospitalizations for HE and all-cause hospitalization at 3 months of dosing（

0.05）. The mean times of hospitalizations for HE ［（0.52±0.86） vs. （1.12±1.04），

=0.000］ and all-cause hospitalizations［（0.90±0.98） vs. （1.60±1.08），

=0.000］ were reduced in the 3 months fo

llowing rifaximin administration compared to the 3 months prior to administration. Subgroup analysis revealed a statistically significant difference in the number of hospitalizations for he and all-cause hospitalizations in both the intermittent and regular dosing groups at 3 months after dosing compared to 3 months before dosing（

0.05）. Patients in the regular dosing group had a higher proportion of stools containing fungi（4/7 vs. 1/10），but the difference was not statistically significant（

=0.101）.

Conclusion

Intermittent use of rifaximin for the prevention of HE is non-inferior to regular use. Both intermittent and regular use of rifaximin can reduce the number of patients hospitalized for HE and all-cause hospitalization after dosing. Long-term use in the clinic requires caution about the risk of fungal infection.

关键词

Keywords

references

中华医学会肝病学分会 . 肝硬化肝性脑病诊疗指南 [J ] . 中华肝脏病杂志， 2018 ， 26 （ 10 ）： 721 - 736 .

Chinese Society of Hepatology, Chinese Medical Association . Guidelines for the diagnosis and management of hepatic encephalopathy in cirrhosis [J ] . Chin J Hepatol , 2018 , 26 ( 10 ): 721 - 736 .

Saab S . Evaluation of the impact of rehospitalization in the management of hepatic encephalopathy [J ] . Int J Gen Med ， 2015 ， 8 ： 165 - 173 .

Caraceni P ， Vargas V ， Solà ， et al . The use of rifaximin in patients with cirrhosis [J ] . Hepatology ， 2021 ， 74 （ 3 ）： 1660 - 1673 .

Loguercio C ， Federico A ， de Girolamo V ， et al . Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study [J ] . Minerva Gastroenterol Dietol ， 2003 ， 49 （ 1 ）： 53 - 62 .

Moniuszko A ， Rydzewska G . The effect of cyclic rifaximin therapy on symptoms of diverticular disease from the perspective of the gastroenterology outpatient clinic：a real-life study [J ] . Prz Gastroenterol ， 2017 ， 12 （ 2 ）： 145 - 151 .

Pietrzak AM ， Dziki A ， Banasiewicz T ， et al . Cyclic rifaximin therapy effectively prevents the recurrence of symptoms after exacerbation of symptomatic uncomplicated diverticular disease：a retrospective study [J ] . Prz Gastroenterol ， 2019 ， 14 （ 1 ）： 69 - 78 .

Cuomo R ， Barbara G ， Annibale B . Rifaximin and diverticular disease：position paper of the Italian society of gastroenterology（SIGE） [J ] . Dig Liver Dis ， 2017 ， 49 （ 6 ）： 595 - 603 .

Jiang ZD ， Ke S ， Palazzini E ， et al . In vitro activity and fecal concentration of rifaximin after oral administration [J ] . Antimicrob Agents Chemother ， 2000 ， 44 （ 8 ）： 2205 - 2206 .

Hudson M ， Radwan A ， di Maggio P ， et al . The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy：a retrospective observational study（IMPRESS） [J ] . Frontline Gastroenterol ， 2017 ， 8 （ 4 ）： 243 - 251 .

Oey RC ， Buck LEM ， Erler NS ， et al . The efficacy and safety of rifaximin-α：a 2-year observational study of overt hepatic encephalopathy [J ] . Therap Adv Gastroenterol ， 2019 ， 12 ： 1756284819858256 .

Hiramine Y ， Uto H ， Mawatari S ， et al . Efficacy of rifaximin，a poorly absorbed rifamycin antimicrobial agent，for hepatic encephalopathy in Japanese patients [J ] . Hepatol Res ， 2021 ， 51 （ 4 ）： 445 - 460 .

Volk ML ， Burne R ， Guérin A ， et al . Hospitalizations and healthcare costs associated with rifaximin versus lactulose treatment among commercially insured patients with hepatic encephalopathy in the United States [J ] . J Med Econ ， 2021 ， 24 （ 1 ）： 202 - 211 .

Abdel Moneim M ， Abdelaziz DH ， Ibrahim Nagy Y ， et al . Rifaximin microbial resistance and its efficacy and safety as a secondary prophylaxis of hepatic encephalopathy in patients with hepatitis C virus-related cirrhosis [J ] . Int J Clin Pract ， 2021 ， 75 （ 11 ）： e14807 .

Chang C ， Huang CH ， Tseng HJ ， et al . Real-world experience of the one-year efficacy of rifaximin add-on to lactulose is superior to lactulose alone in patients with cirrhosis complicated with recurrent hepatic encephalopathy in Taiwan [J ] . J Pers Med ， 2021 ， 11 （ 6 ）： 478 .

Hudson M ， Schuchmann M . Long-term management of hepatic encephalopathy with lactulose and/or rifaximin：a review of the evidence [J ] . Eur J Gastroenterol Hepatol ， 2019 ， 31 （ 4 ）： 434 - 450 .

Chautant F ， Guillaume M ， Robic MA ， et al . Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy [J ] . World J Hepatol ， 2020 ， 12 （ 1 ）： 10 - 20 .

Jesudian AB ， Ahmad M ， Bozkaya D ， et al . Cost-effectiveness of rifaximin treatment in patients with hepatic encephalopathy [J ] . J Manag Care Spec Pharm ， 2020 ， 26 （ 6 ）： 750 - 757 .

Berni E ， Murphy D ， Whitehouse J ， et al . Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom [J ] . Curr Med Res Opin ， 2018 ， 34 （ 11 ）： 2001 - 2008 .

de Jong LA ， van Schoonhoven AV ， Hofstra HS ， et al . Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands [J ] . J Med Econ ， 2021 ， 24 （ 1 ）： 1149 - 1163 .

Neff G ， Zachry W III . Systematic review of the economic burden of overt hepatic encephalopathy and pharmacoeconomic impact of rifaximin [J ] . Pharmacoeconomics ， 2018 ， 36 （ 7 ）： 809 - 822 .

Kawaguchi T ， Suzuki F ， Imamura M ， et al . Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy：an exploratory data analysis of phase II/III clinical trials [J ] . Hepatol Res ， 2019 ， 49 （ 4 ）： 404 - 418 .

Kaji K ， Takaya H ， Saikawa S ， et al . Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity [J ] . World J Gastroenterol ， 2017 ， 23 （ 47 ）： 8355 - 8366 .

Schulz C ， Schütte K ， Vilchez-Vargas R ， et al . Long-term effect of rifaximin with and without lactulose on the active bacterial assemblages in the proximal small bowel and faeces in patients with minimal hepatic encephalopathy [J ] . Dig Dis ， 2019 ， 37 （ 2 ）： 161 - 169 .

Yu X ， Jin Y ， Zhou WX ， et al . Rifaximin modulates the gut microbiota to prevent hepatic encephalopathy in liver cirrhosis without impacting the resistome [J ] . Front Cell Infect Microbiol ， 2021 ， 11 ： 761192 .

Bajaj JS ， Khoruts A . Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis [J ] . J Hepatol ， 2020 ， 72 （ 5 ）： 1003 - 1027 .

中国研究型医院学会肝病专业委员会重症肝病学组，中华医学会肝病学分会重型肝病与人工肝学组 . 重症肝病合并侵袭性真菌感染诊治专家共识 [J ] . 中华肝脏病杂志， 2022 ， 30 （ 2 ）： 159 - 168 .

Severe Liver Disease Group , the Professional Committee for Hepatology , Chinese Research Hospital Association , Severe Liver Disease and Artificial Liver Group , Chinese Society of Hepatology , Chinese Medical Association . Consensus on diagnosis and treatment of invasive fungal infection in patients with severe liver disease [J ] . Chin J Hepatol ， 2022 ， 30 （ 2 ）： 159 - 168 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research of lycium barbarum polysccharide in the prevention and treatment of non-alcoholic fatty liver disease at cellular level

CHANGE OF BRAIN UPTAKE OF BLOOD GABA IN EXPERIMENTAL HEPATIC ENCEPHALOPATHY IN MICE

THE IN VITRO INHIBITION OF CEREBRAL GABA DEGRADATION BY THE LIVER HOMOGENATE SUPERNATANT OF MICE

STUDIES ON GABA-T AND ITS INHIBITOR IN MICE WITH HEPATIC ENCEPHALOPATHY

DETERMINATION AND CLINICAL SIGNIFICANCE OF CONCENTRATIONS OF PLASMA AMMONIA, SERUM TRYPTOPHAN, SEROTONIN AND 5-HYDROXYINDOLACETIC ACID IN PATIENTS WITH HEPATIC ENCEPHALOPATHY

Related Author

Gu Sai

Guo Pengli

王征泰

Department of Biochemistry Li Qian Wang Zhengtai

Wang Zhengtai

He Tongchaun

Jiang Xiaoqiu

王征泰

Related Institution

Department of Gastroenterology,The First Affiliated Hospital of Chongqing Medical University

重庆医科大学生化教研室

Department of Biochemistry

重庆医科大学第二医院重庆医科大学第二医院研究生

重庆医科大学第二医院研究生

⁰